Mitsubishi Tanabe Pharma

Product Strategy & Development Pipeline

November 1, 2010
2Q, FY2010 Business Results Briefing
Hotel Metropolitan Edmont

Seiichi Murakami
Division Manager
Development Division

Agenda

Mitsubishi Tanabe Pharma

1. Development Pipeline Status
2. Major Development Projects
   - Overseas Development Status
   - Diabetes
   - Autoimmune diseases
   - Others

1. Development Pipeline Status

1. Development Pipeline Status

＜ *Japan* ＞

Mitsubishi Tanabe Pharma

Changes since announcement of Financial Results for FY2009 (12 May, 2010)



＜*Overseas*＞ In-house developments, licensed products

Mitsubishi Tanabe Pharma

Changes since announcement of Financial Results for FY2009 (12 May, 2010)

: Stage Up

Overseas (in-house development products)

Phase 1	Phase 2	Phase 3	Filed
MP-124 (Stroke)	MCI-186 (Stroke)	MCI-196 (Hyperphosphatemia)	Argatroban** (HIT)
MP-136 (Dyslipidemia)	MP-513 (Type 2 Diabetes Mellitus)	MP-146 (Chronic Kidney Disease)	
TA-8995 (Dyslipidemia)	MT-2832 (Secondary Hyperparathyroidism)		
MT-3995 (Hypertention)			
GB-1057 (Stabilizing Agent)			

Overseas (main licensed products)

Phase 2	Phase 3	Filed
TA-7284 (Obesity)	TA-7284 (Type 2 Diabetes Mellitus)	FTY720 (Multiple Sclerosis) EU
T-0047 (Multiple Sclerosis)	TA-1790 (US) (Erectile Dysfunction)	
	TA-1790 (Korea)* (Erectile Dysfunction)	

- Metabolism/ Cardiovascular
- Immunology
- CNS
- Others

* Rolling submission is on going

** Preparing for filing

Lisensed out product

Approved

FTY720 (Multiple Sclerosis) US and Russia

2. Major Development Products

Overseas Development Status

Major Development Projects [Overseas]

Mitsubishi Tanabe Pharma



Diabetes

MP-513 / Teneligliptin (Type2 Diabetes)

Mitsubishi Tanabe Pharma

【Status of Development】

Japan: Phase 3

US/Europe: Phase 2

- Under negotiation for licensing

■ Development stage prediction of DPP4 inhibitors in Japan

Launched	Sitagliptin Vildagliptin Alogliptin
Phase 3	Linagliptin Teneligliptin (MTPC) SK0403 Saxagliptin

■ Characteristics

- Improves glycemic control by an oral once daily administration for the 24hr continuously
- Low excretion rate from kidneys (possible potential no dosage adjustment is required on the patients with low kidney functions)

Teneligliptin : P2a Study in Japan

Mitsubishi Tanabe Pharma

HbA1c changes at 12 week



＊The data are expressed as LS mean values±S.E.

Source: Presentation slides at Japan Diabetes Society in May, 2010 by Dr. Takashi Kadowaki (partially modified)

TA-7284 / Canagliflozin (Diabetes)

Mitsubishi Tanabe Pharma

【Status of Development】

Japan: Phase 2 by MTPC

US/Europe: Phase 3, licensed out

Development by Johnson & Johnson Pharmaceutical Research & Development, LLC (Planned filing 2012)

■ Development stage predictions of SGLT2 inhibitors

(Japan)

Phase 3	ASP1941 BI10773
Phase 2	RG7201/CSG452 Dapagliflozin TA-7284 (Canagliflozin)

(Overseas)

Phase 3	Dapagliflozin TA-7284/Canagliflozin BI10773
Phase 2	RG7201/CSG452 ASP1941 LX-4211

■Characteristics

Potent blood glucose lowering + weight reduction

Insulin-independent mechanism

■Presented the Results of Clinical Trials

:Japan Diabetes Society (May), American Diabetes Association (June)
European Association for the Study of Diabetes (Sep.)

Canagliflozin : Overseas P2b Study

Mitsubishi Tanabe Pharma

HbA1c Changes at 12 week



*P<0.001 vs placebo calculated using LS means.

"Canagliflozin is being developed by Johnson & Johnson Pharmaceutical Research and Development, LLC in collaboration with Mitsubishi Tanabe Pharma Corporation."

Source: Presentation slides at ADA on June 26, 2010 by Dr. Julio Rosenstock (partially modified)

Canagliflozin : Overseas P2b Study

Mitsubishi Tanabe Pharma

Body Weight Changes at 12week

SGLT2 Inhibition for Type 2 DM: MET + Canagliflozin Dose-Ranging Study



*P<0.01 vs placebo calculated using LS means.

"Canagliflozin is being developed by Johnson & Johnson Pharmaceutical Research and Development, LLC in collaboration with Mitsubishi Tanabe Pharma Corporation."

Source: Presentation slides at ADA on June 26, 2010 by Dr. Julio Rosenstock (partially modified)

Auto Immune Diseases

FTY720 （Multiple Sclerosis）

Mitsubishi Tanabe Pharma

【Development status】

- Overseas： Licensed out to Novartis Pharma
  Approved in Russia and the USA in September
  Q4'10: Expected Switzerland approval
  Q1'11: Expected EMA approval, Germany & UK launch
- Japan： preparing for filing by the end of 2010
  （Co-development with Novartis Pharma K.K.）

【Competitors】

- Oral administration drugs

(Overseas)

Approved	Cladribine
Phase3	Panaclar/ BG-12 （Dimethyl fumarate ） Laquinimod/ ABR215062 Teriflunomide/ HMR1726

Remicade (Life Cycle Management)

Mitsubishi Tanabe Pharma

Changes since announcement of Financial Results for FY2009 (12 May., 2010)

: Stage Up



CD: Crohn's disease
RA: Rheumatoid arthritis
BD: Behcet's disease (uveoretinitis)
AS: Ankylosing spondylitis
UC: Ulcerative colitis

Remicade: Ulcerative colitis : P3 results in Japan



logistic regression model with treatment group and use of steroids upon registration as explanatory variables

Remicade:
Comparison with Other Biologics (Japan)

Mitsubishi Tanabe Pharma

	Anti-TNFα antibody					Anti-IL-6 receptor antibody	CTLA4-Ig
Product name	Remicade	Enbrel	Humira	Golimumab	Cimzia	Actemra	Orencia
RA approval	2003	2005	2008	Under development	Under development	2008	2010
Company	MTPC	Takeda /Pfizer	Abbott /Eisai	Janssen /MTPC	UCB /Otsuka	Chugai	BMS
Indications	RA, CD BD, Ps AS, UC	RA JIA	RA, Ps CD, AS (JIA, UC)	(RA, UC)	(RA、CD)	Castleman, RA, JIA	RA
Administration method	IV	SC	SC	SC	SC	IV	IV
Administration interval	Every 8 weeks	Once or twice-weekly	Every 2 weeks	Every 4 weeks	Every 4 weeks	Every 4 weeks	Every 4 weeks

RA Rheumatoid Arthritis
CD Crohn's disease
BD Behcet's disease
Ps Psoriasis
AS Ankylosing Spondylitis
UC Ulcerative Colitis
JIA Juvenile Idiopathic Arthritis

( )Under development
IV : Intravenous Injection
SC :Subcutaneous Injection

CNTO148/ Golimumab (Rheumatoid Arthritis)

Mitsubishi Tanabe Pharma

【Development Status】

・Japan: Co-development(Janssen Pharma)

sNDA filed in June, 2010 by Janssen Pharma

・Overseas: Launched in Europe and US

(by Johnson and Johnson/MSD)

【Mechanism・Product profile】

・Anti-TNFα monoclonal antibody

・Injection solution for subcutaneous use

・Once per month

Others

MP-424 Telaprevir （Chronic Hepatitis C）

Mitsubishi Tanabe Pharma

【Indication 】 Chronic Hepatitis C

【MOA 】 NS3/4A protease inhibitor

【Characteristics】 High efficacy , Short treatment period

【Development status 】

Japan： Preparing for filing

Overseas： Rolling submission is on going by Vertex Pharma

【Development status in Japan】

(P2 stage)

TMC435 Vaniprevir (MK-7009)	Protease inhibitor
BMS-790052	NS5A inhibitor

Telaprevir : P3 results in Japan



(PEG-IFN, RBV,48week)



(MP-424, 12week、 PEG-IFN, RBV, 24week)

Overseas P3 results (ADVANCE)





Overseas P3 results (REALIZE)

(Telaprevir- based treatments)

Mitsubishi Tanabe Pharma

Cautionary Statement

The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties. Actual financial results may differ materially from these forecasts depending on a number of important factors.